We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Has Trevena (TRVN) Outpaced Other Medical Stocks This Year?
Read MoreHide Full Article
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Trevena (TRVN - Free Report) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
Trevena is one of 931 individual stocks in the Medical sector. Collectively, these companies sit at #14 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. TRVN is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for TRVN's full-year earnings has moved 14% higher within the past quarter. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Our latest available data shows that TRVN has returned about 208% since the start of the calendar year. At the same time, Medical stocks have lost an average of 1.32%. This means that Trevena is performing better than its sector in terms of year-to-date returns.
Breaking things down more, TRVN is a member of the Medical - Biomedical and Genetics industry, which includes 414 individual companies and currently sits at #178 in the Zacks Industry Rank. This group has lost an average of 3.25% so far this year, so TRVN is performing better in this area.
TRVN will likely be looking to continue its solid performance, so investors interested in Medical stocks should continue to pay close attention to the company.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Has Trevena (TRVN) Outpaced Other Medical Stocks This Year?
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Trevena (TRVN - Free Report) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
Trevena is one of 931 individual stocks in the Medical sector. Collectively, these companies sit at #14 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. TRVN is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for TRVN's full-year earnings has moved 14% higher within the past quarter. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Our latest available data shows that TRVN has returned about 208% since the start of the calendar year. At the same time, Medical stocks have lost an average of 1.32%. This means that Trevena is performing better than its sector in terms of year-to-date returns.
Breaking things down more, TRVN is a member of the Medical - Biomedical and Genetics industry, which includes 414 individual companies and currently sits at #178 in the Zacks Industry Rank. This group has lost an average of 3.25% so far this year, so TRVN is performing better in this area.
TRVN will likely be looking to continue its solid performance, so investors interested in Medical stocks should continue to pay close attention to the company.